Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: April 02, 2022
Accepted: September 07, 2022
Published online: December 07, 2022
Issue release date:

Number of Print Pages: 10
Number of Figures: 7
Number of Tables: 7

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: https://www.karger.com/ACY

Abstract

Introduction: The International Academy of Cytology and the American Society of Cytopathology recently proposed the International System for Reporting Serous Fluid Cytology (ISRSFC) to standardize serous fluid cytopathology reporting and guide further clinical management. The current study aimed to assess the feasibility of utilizing ISRSFC reporting categories for serous fluids, estimate the risk of malignancy (ROM) of each category, and scrutinize if the management protocols followed in our institution are as per the ISRFSFC recommendations. Methods: All pleural, peritoneal, and pericardial effusions submitted for evaluation at our institute between January 2021 and December 2021 were retrieved. All these cases were reviewed and re-categorized into one of the five categories proposed by the ISRSFC: non-diagnostic (ND), negative for malignancy (NFM), atypia of uncertain significance (AUS), suspicious for malignancy (SFM), and malignant (MAL), and ROM was calculated for each category. Results: The present study examined 596 serous effusions, of which 229 were pleural effusions, 358 were peritoneal effusions, and the remaining nine were pericardial effusions. Among 596 cases, 395 cases had a radiological or histological follow-up. The serous effusion samples were re-categorized as 61 (10.2%) ND, 449 (75.3%) NFM, 47 (7.8%) AUS, 17 (2.9%) SFM, and 22 (3.8%) MAL, and ROM for each above category were 10%, 4.4%, 19%, 83.3%, and 100%, respectively. Conclusion: Categorizing serous effusion cytology samples per the ISRSFC diagnostic categories reduces reporting variability. The ISRSFC provides a standardized format to predict the ROM and thus improves the quality of clinical care.

© 2022 S. Karger AG, Basel

References Michael CW. Serous fluid cytopathology: past, present, and future. Diagn Cytopathol. 2021;49(5):577–81. Pitman MB, Layfield LJ. Guidelines for pancreaticobiliary cytology from the Papanicolaou society of cytopathology: a review. Cancer Cytopathol. 2014;122(6):399–411. Nayar R, Wilbur D. The Bethesda system for reporting cervical cytology: definitions, criteria, and explanatory notes. Berlin/Heidelberg, Germany: Springer; 2015. Rosenthal DL, Wojcik EM, Kurtycz DFI. The Paris system for reporting urinary cytology. Berlin/Heidelberg, Germany: Springer; 2015. Layfield LJ, Baloch Z, Elsheikh T, Litzky L, Rektman N, Travis WD, et al. Standardized terminology and nomenclature for respiratory cytology: the Papanicolaou society of cytopathology guidelines. Diagn Cytopathol. 2016;44(5):399–409. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341–6. Faquin WC, Rossi ED, Baloch Z, Barkan GA, Foschini MP, Kurtycz DFI, et al. The milan system for reporting salivary gland cytopathology. Berlin/Heidelberg, Germany: Springer; 2018. Field AS, Raymond WA, Rickard M, Arnold L, Brachtel EF, Chaiwun B, et al. The international academy of cytology yokohama system for reporting breast fine-needle aspiration biopsy cytopathology. Acta Cytol. 2019;63(4):257–73. Chandra A, Crothers B, Kurtycz D, Schmitt F. Announcement: the international system for reporting serous fluid cytopathology. Acta Cytol. 2019;63(5):349–51. Crothers BA, Chandra A. Proceedings of the American Society of cytopathology companion session at the 2019 United States and Canadian Academy of Pathology meeting Part 1: towards an international system for reporting serous fluid cytopathology. J Am Soc Cytopathol. 2019;8(6):362–8. Chandra A, Crothers B, Iyama-Kurtycz D, Schmitt F. The international system for serous fluid cytopathology. Berlin/Heidelberg, Germany: Springer; 2020. Pinto D, Chandra A, Crothers BA, Kurtycz DFI, Schmitt F. The international system for reporting serous fluid cytopathology-diagnostic categories and clinical management. J Am Soc Cytopathol. 2020;9(6):469–77. Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012;4(4):87–95. Lobo C, Costa J, Petronilho S, Monteiro P, Leça L, Schmitt F. Cytohistological correlation in serous effusions using the newly proposed international system for reporting serous fluid cytopathology: experience of an oncological center. Diagn Cytopathol. 2021;49(5):596–605. Rodriguez EF, Jones R, Gabrielson M, Santos D, Pastorello RG, Maleki Z. Application of the International System for Reporting Serous Fluid Cytopathology (ISRSFC) on reporting pericardial effusion cytology. Acta Cytol. 2020;64(5):477–85. Hou T, Landon G, Stewart J, Roy-Chowdhuri S. The value of a tiered cytology diagnostic reporting system in assessing therisk of malignancy in indeterminate serous effusions. Cancer Cytopathol. 2021;129(1):75–82. Xu Y, Hu AY, Wang SM, Wang Q, Pan YC, Zhang SH. A retrospective analysis of pleural effusion specimens based on the newly proposed international system for reporting serous fluid cytopathology. Diagn Cytopathol. 2021;49(9):997–1007. Jha S, Sethy M, Adhya AK. Application of the International System for Reporting Serous Fluid Cytopathology in routine reporting of pleural effusion and assessment of the risk of malignancy. Diagn Cytopathol. 2021;49(10):1089–98. Kundu R, Srinivasan R, Dey P, Gupta N, Gupta P, Rohilla M, et al. Application of Indian academy of cytologists guidelines for reporting serous effusions: an institutional experience. J Cytol. 2021;38(1):1–7. Swiderek J, Morcos S, Donthireddy V, Surapaneni R, Jackson-Thompson V, Schultz L, et al. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest. 2010;137(1):68–73. Thomas SC, Davidson LRR, McKean ME. An investigation of adequate volume for the diagnosis of malignancy in pleural fluids. Cytopathology. 2011;22(3):179–84. Rooper LM, Ali SZ, Olson MT. A minimum volume of more than 60 mL is necessary for adequate cytologic diagnosis of malignant pericardial effusions. Am J Clin Pathol. 2016;145(1):101–6. Pinto D, Cruz E, Branco D, Linares C, Carvalho C, Silva A, et al. Cytohistological correlation in pleural effusions based on the international system for reporting serous fluid cytopathology. Diagnostics. 2021;11(6):1126. Farahani SJ, Baloch Z. Are we ready to develop a tiered scheme for the effusion cytology? A comprehensive review and analysis of the literature. Diagn Cytopathol. 2019;47(11):1145–59. Article / Publication Details

First-Page Preview

Received: April 02, 2022
Accepted: September 07, 2022
Published online: December 07, 2022
Issue release date:

Number of Print Pages: 10
Number of Figures: 7
Number of Tables: 7

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: https://www.karger.com/ACY